RWJ-394674: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 24: | Line 24: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
<gallery> | |||
File:RWJ-394674 Structure.svg|RWJ-394674 Structure | |||
</gallery> | |||
Latest revision as of 01:44, 20 February 2025
RWJ-394674 is a chemical compound that belongs to the class of benzimidazole derivatives. It is a potent and selective inhibitor of the enzyme neprilysin (also known as neutral endopeptidase, NEP).
Chemistry[edit]
RWJ-394674 is a synthetic compound that contains a benzimidazole core structure. The benzimidazole ring is a heterocyclic aromatic organic compound that is a fusion of benzene and imidazole. The compound is characterized by its high selectivity and potency as a neprilysin inhibitor.
Pharmacology[edit]
RWJ-394674 acts by inhibiting the enzyme neprilysin, which is involved in the degradation of a number of bioactive peptides in the body. By inhibiting neprilysin, RWJ-394674 increases the levels of these peptides, which can have various physiological effects. For example, increased levels of natriuretic peptides can lead to increased diuresis and vasodilation, which can be beneficial in conditions such as heart failure.
Clinical significance[edit]
The inhibition of neprilysin has been investigated as a potential therapeutic strategy in a number of conditions, including heart failure and hypertension. RWJ-394674, with its high selectivity and potency as a neprilysin inhibitor, has therefore been the subject of research in these areas. However, as of now, it is not approved for use in any country and is only used in research settings.
See also[edit]
-
RWJ-394674 Structure
